Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - carfentrazone-ethyl; n-methyl-2-pyrrolidone; liquid hydrocarbon - emulsifiable concentrate - carfentrazone-ethyl ungrouped active 400.0 g/l; n-methyl-2-pyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 452.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - famotidine, quantity: 40 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; purified talc; magnesium stearate; purified water; titanium dioxide; hypromellose; indigo carmine; quinoline yellow; iron oxide yellow; iron oxide red; macrogol 400 - duodenal ulcer; benign gastric ulcer; zollinger-ellison syndrome; prevention of relapses of duodenal ulceration; short-term (no more than 12 weeks) symptomatic relief of gastroesophageal reflux not responsive to conservative measures; healing of oesophageal erosion or ulceration associated with gastroesophageal reflux disease; prevention of relapses of symptoms and erosions or ulcerations associated with gastroesophageal reflux disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - famotidine, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; purified talc; magnesium stearate; purified water; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400 - duodenal ulcer; benign gastric ulcer; zollinger-ellison syndrome; prevention of relapses of duodenal ulceration; short-term (no more than 12 weeks) symptomatic relief of gastroesophageal reflux not responsive to conservative measures; healing of oesophageal erosion or ulceration associated with gastroesophageal reflux disease; prevention of relapses of symptoms and erosions or ulcerations associated with gastroesophageal reflux disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - naloxone hydrochloride dihydrate, quantity: 400 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; dilute hydrochloric acid - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval for listing of these goods as pharmaceutical benefits were approved as specified in the letter of 29 october 1992 from dr alex proudfoot. indications: for the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and the narcotic-antagonist analgesics such as nalbuphine, methadone and butorphanol. indications as at 8 january 2004: naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 46585 - prosthesis, knee, internal, insert component - the pfc sigma curved rp insert articulates with the femoral component and rotates on the surface of the tibial tray of a knee joint prosthesis. it is a one-piece contoured uhmwpe insert. the pfc sigma curved rp insert is an articulating component of the lcs complete ? pfc sigma rp mobile bearing total knee system. the lcs complete ? pfc sigma rp mobile bearing total knee system is intended for cemented use in cases of osteoarthritis and rheumatoid arthritis. the rotating platform stabilised insert is indicated where a higher than normal degree of post-operative flexion is required. the porous coated keeled and non-keeled mbt (mobile bearing tibial) tray configurations of the lcs total knee system are indicated for noncemented use in skeletally mature individuals undergoing primary surgery for reconstructing knees damaged as a result of noninflammatory degenerative joint disease (nidjd) or either of its composite diagnoses of osteoarthritis and post traumatic arthritis pathologies. the rotating platform device configuration is indicated for use in knees whose anterior and posterior cruciate ligaments are absent or are in such condition as to justify their sacrifice. the pfc sigma curved bearings when used with the pfc sigma cruciate retaining femoral component can be used in posterior cruciate ligament retaining procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 46585 - prosthesis, knee, internal, insert component - the pfc sigma tc3 rp inserts are manufactured from uhmwpe and reinforced with titanium alloy pins. the pfc sigma tc3 rp inserts articulate with the m.b.t. primary and revision trays. the pfc sigma tc3 rp insert is the articulating component of the lcs complete ? pfc sigma rp mobile bearing total knee system. the lcs complete ? pfc sigma rp mobile bearing total knee system is indicated for cemented use in cases of osteoarthritis and rheumatoid arthritis. the rpf and rps inserts and femoral components are indicated where a higher than normal degree or post-operative flexion is required. the rotating platform prosthesis and modular revision components are indicated for revision of failed knee prosthesis.

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 46585 - prosthesis, knee, internal, insert component - the pfc sigma rp stabilised tibial insert articulates with the femoral component and rotates on the surface tibial tray of a knee joint prosthesis. it is a one-piece contoured polymer insert. the pfc sigma rp stabilised tibial inserts is an articulating component of the lcs complete pfc sigma rp mobile bearing total knee system. the pfc sigma knee system is intended to provide increased patient mobility and reduce pain by replacing the damaged knee joint articulation in skeletally mature patients with a severely painful knee and impaired knee function where there is evidence of sufficient sound bone to seat and support the components. its indications include: - a severely painful and/or disabled joint (typically due to non inflammatory degenerative joint disease) - failed previous knee surgery

Australia - English - Department of Health (Therapeutic Goods Administration)

johnson & johnson medical pty ltd t/a depuy synthes - 46585 - prosthesis, knee, internal, insert component - the pfc sigma duofix insert articulates with the femoral component and snap locks into the tibial tray of a knee joint prosthesis. it is a one-piece contoured polyethylene insert. the pfc sigma duofix insert is the articulating component of a total knee arthroplasty and is intended to provide increased patient mobility and reduced pain by replacing the damaged knee joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. candidates for total knee replacement include patients with a severely painful and/or severely disabled joint resulting from osteoarthritis, post-traumatic arthritis, rheumatoid arthritis, or failed previous implant.